 |
|
COMMENTS AND OPINIONS
Association of Proliferative Diabetic Retinopathy With Insulin Use and Microalbuminuria
Shu-Hsun Chu, MD, PhD;
Ai-Hsien Li, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The article by Shen and colleagues1 reminded us of the potential role of oral peroxisome-proliferative activated receptor  -agonists, not only in the control of blood glucose, but in the delayed onset of proliferative diabetic retinopathy (PDR). The authors argue that "Rosiglitazone may delay the onset of PDR probably because of its antiangiogenic activity." However, there are 2 major concerns to address before we seriously consider this argument, regarding the basal demographic profile in Table 1.
Because this is a retrospective study, well-matched data comparing the treatment group and controls is essential before drawing any conclusions; any significant discrepancy in the patients' profiles could be disastrously confounding to the authors' original design. As shown in Table 1, the control patients have significantly more use of insulin than rosiglitazone group. There have been several articles in the literature suggesting that the use of insulin would . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy
Lucy Q. Shen, Angie Child, Griffin M. Weber, Judah Folkman, and Lloyd Paul Aiello
Arch Ophthalmol. 2008;126(6):793-799.
ABSTRACT
| FULL TEXT
RELATED LETTER
Association of Proliferative Diabetic Retinopathy With Insulin Use and Microalbuminuria—Reply
Lloyd Paul Aiello and Lucy Q. Shen
Arch Ophthalmol. 2010;128(1):146-147.
EXTRACT
| FULL TEXT
|
